{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T11:52:07Z","timestamp":1721562727083},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.2169\/internalmedicine.6029-20","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T22:07:03Z","timestamp":1614550023000},"page":"745-750","source":"Crossref","is-referenced-by-count":4,"title":["Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis"],"prefix":"10.2169","volume":"60","author":[{"given":"Ryotaro","family":"Sakamori","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Shinkai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tahata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Shigekawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Medical Innovation, Osaka University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 71: 686-721, 2020.","DOI":"10.1002\/hep.31060"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Younossi ZM, Stepanova M, Gordon S, et al. Patient-reported outcomes following treatment of chronic hepatitis C virus infection with sofosbuvir and velpatasvir, with or without voxilaprevir. Clin Gastroenterol Hepatol 16: 567-574, 2018.","DOI":"10.1016\/j.cgh.2017.11.023"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sugimoto R, Iwasa M, Hara N, et al. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res 48: 337-344, 2018.","DOI":"10.1111\/hepr.12999"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hiraoka A, Kitahata S, Izumoto H, et al. Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension. Hepatol Res 48: E354-E359, 2018.","DOI":"10.1111\/hepr.12984"},{"key":"5","unstructured":"5. Kang SH, Jeong WK, Baik SK, et al. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle 9: 860-870, 2018."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hanai T, Shiraki M, Ohnishi S, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res 46: 743-751, 2016.","DOI":"10.1111\/hepr.12616"},{"key":"7","unstructured":"7. Nishikawa H, Shiraki M, Hiramatsu A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 46: 951-963, 2016."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology 156: 446-460, 2019.","DOI":"10.1053\/j.gastro.2018.10.033"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Endo K, Sato T, Suzuki A, et al. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. J Gastroenterol Hepatol 35: 1602-1609, 2020.","DOI":"10.1111\/jgh.14991"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yoh K, Nishikawa H, Enomoto H, et al. Predictors associated with increase in skeletal muscle mass after sustained virological response in chronic hepatitis C treated with direct acting antivirals. Nutrients 9: 1135, 2017.","DOI":"10.3390\/nu9101135"},{"key":"11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","volume":"151","author":"V Di Marco","year":"2016","unstructured":"11. Di Marco V, Calvaruso V, Ferraro D, et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 151: 130-139, 2016.","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kitajima Y, Takahashi H, Akiyama T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis. J Gastroenterol 53: 427-437, 2018.","DOI":"10.1007\/s00535-017-1370-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 154: 2111-2121, 2018.","DOI":"10.1053\/j.gastro.2018.03.022"},{"key":"14","unstructured":"14. Tanaka A; Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 50: 791-816, 2020."},{"key":"15","unstructured":"15. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 67: 1477-1492, 2018."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69: 461-511, 2018.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"17","unstructured":"17. Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol 54: 87-95, 2019."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Taniyama O, Mawatari S, Oda K, et al. Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1b. Hepatol Res 49: 239-243, 2019.","DOI":"10.1111\/hepr.13235"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/5\/60_6029-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T04:09:19Z","timestamp":1615003759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/5\/60_6029-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6029-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}